A bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chan, Kelvin ^a   Shah, Keya ^a   Lien, Kelly ^a   Coyle, Doug ^b   Lam, Henry ^a   Ko, Yoo Joung ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; META ANALYSIS; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BAYES THEOREM; CANCER STAGING; COMPARATIVE STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; DEOXYCYTIDINE; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84907813913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108749     Document Type: Article

References (40)

1. American Cancer Society (2013) Cancer facts and figures 2013. Available:
2. Office for National Statistics (2011) Cancer Survival in England patients diagnosed 2005-2009 followed up to 2010. Available: Accessed 2014 July 4.
3. War same R, Grothey A (2012) Treatment options for advanced pancreatic cancer: A review. Expert Rev Anticancer Ther 12: 1327-36.
4. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363: 1049-57.
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-13.
6. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, et al. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-7.
7. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-8.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-6.
9. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, et al. (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19: 340-7.
10. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, et al. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-52.
11. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, et al. (2012) Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol suppl 34: abstract LBA148.
12. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-25.
13. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K (2011) Network metaanalysis-highly attractive but more methodological research is needed. BMC Med 9: 79.
14. Wells GA, Sultan SA, Chen L, Khan M, Coyle D (2009) Indirect Evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available: products/health-technology-assessment/publication/884 Accessed 2014July 4.
15. (2008) Erlotinib for the treatment of non-small-cell lung cancer. London: National Institute for Health and Clinical Excellence. Available: . nice.org.uk/Guidance/TA162 Accessed 2014 July 4.
16. Higgins JP, Altman DG (2008) Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Wiley, pp. 187-241.
17. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-34.
18. Sutton AJ, Abrams KR (2001) Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10: 277-303.
19. Higgins JP, Thompson SG, Decks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
20. Ntzoufras I (2009) Bayesian modeling using WinBUGS. New York: Wiley. 220 P.
21. Hoglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, et al. (2011) Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices -Part 2. Value Health 14: 429-437.
22. Altman DG, Andersen PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319: 1492-1495.
23. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, et al. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-5.
24. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dellItalia Meridionale. Cancer 94: 902-10.
25. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, et al. (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with singleagent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28: 1645-51.
26. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, et al. (2005) Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 93: 185-9.
27. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL et al. (2009) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 27: 5506-12.
28. Li CP, Chao Y (2004) A prospective randomized trial of gemcitabine alone or gemcitabine plus cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22: Abstract 4144.
29. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-16.
30. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, et al. (2012) A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106: 1934-9.
31. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, et al. (2012) Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 69: 1197-204.
32. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, et al. (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778-85.
33. Riess A, Niedergethmann HM, Molk ISM, Hammer C, Zippel K, et al. (2005) A Randomised, Prospective, Multicenter, Phase III trial of Gemcitabine, 5-Fluourouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23: Abstract 4009.
34. Scheithauer W, Schuil B, Ulrich-Pur H, Schmid K, Raderer M, et al. (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104.
35. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, et al. (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31: 1640-8.
36. Viret F, Ychou M, Lepille D, Mineur L, Navarro F, et al. (2004) Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22: Abstract 4118.
37. Wang X, Ni Q, Jin M, Li Z, Wu Y, et al. (2002) Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua zhong liu za zhi. Chinese journal of oncology 24: 404-7.
38. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-703.
39. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, et al. (2009) Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on a Pancreas Cancer Treatment. J Clin Oncology 27: 5660-9.
40. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, et al. (2012) Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 13: 497-501.